|

Xenon Inhalation Therapy for Major Depressive Disorder and Bipolar Disorder

RECRUITINGEarly 1Sponsored by Massachusetts General Hospital
Actively Recruiting
PhaseEarly 1
SponsorMassachusetts General Hospital
Started2019-12-05
Est. completion2026-09-01
Eligibility
Age18 Years – 65 Years
Healthy vol.Accepted
Locations1 site

Summary

The investigators will test the hypothesis that inhaled xenon will produce a rapid improvement in depressive symptoms in patients suffering from treatment-resistant depression. Specifically, the investigators will conduct a parallel randomized, double-blind crossover study that will compare the effects of xenon-oxygen (35:65 ratio by volume) added to treatment as usual (X-TAU group) to the effects of nitrogen-oxygen (35:65 ratio by volume) added to treatment as usual (N-TAU group). A total of 20 severely depressed patients, 10 with major depressive disorder (MDD) and 10 with Bipolar Depression (BP), will be exposed in random order to N-TAU and X-TAU in a double-blind protocol.

Eligibility

Age: 18 Years – 65 YearsHealthy volunteers accepted
Inclusion Criteria:

* Patient who meets DSM-V Criteria for MDD or Bipolar Depression (according to DSM-V), as the primary focus of treatment.
* Able to understand the risks and benefits of participating in this clinical trial and give informed consent, per judgment of the investigator.
* Age greater than or equal to 18 years but less than or equal to 65 years.
* Montgomery Asberg Depression Rating Scale ≥20.
* On an adequate antidepressant regimen (MDD) or on a mood stabilizing regimen (BP) that is stable for at least four weeks prior to enrollment.
* Has reliable adult transportation from and to home.
* Has a treating psychiatrist who is in agreement with the patient's participation in the study, and aware of the safety plan in the protocol.
* No medical contraindications to receiving a xenon- or a nitrogen-oxygen mixture.
* No serious or active pulmonary disease.

Exclusion Criteria:

* MDD or BP disorder with psychosis, schizophrenia, OCD, or a primary anxiety disorder.
* Currently taking a benzodiazepine (including PRN).
* Unwilling or unable to comply with study procedures.
* Active substance abuse in the past 60 days, diagnosis of substance dependence in the past 12 months, currently active smokers of any substance, including prescription marijuana.
* Pregnant women or women of child bearing potential who are not using a medically accepted means of contraception.
* Any unstable medical illness (cardiovascular, hepatic, renal, respiratory, endocrine, neurological, or hematological disease or uncontrolled seizure disorder).
* Any history of brain injury and any active state involving entrapped air/gas within a body cavity with the potential to expand causing organ distension/compression (e.g., bowel obstruction, pneumothorax, or pneumocephalus).
* History of hypersensitivity to xenon; history of multiple adverse drug reactions.
* Have taken any investigational psychotropic drug within the last 6 months.
* Inability to agree to comply with the visit schedule or study procedures.
* Not appropriate for participation in a research trial per judgment of the investigator.

Conditions3

Bipolar DepressionDepressionMajor Depressive Disorder

Locations1 site

Dauten Family Center for Bipolar Treatment Innovation
Boston, Massachusetts, 02114
Andrew Nierenberg, MD

Browse More Trials

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.